Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Transcenta Holding Limited ( (HK:6628) ) is now available.
Transcenta Holding Limited announced promising updated efficacy data from its phase I/II Transtar102 trial involving osemitamab combined with nivolumab and CAPOX for first-line treatment of gastric/gastroesophageal junction cancer. The trial results, presented at the ESMO Asia Congress 2025, showed significant clinical benefits, including a median progression-free survival of 16.6 months and an overall response rate of 68% in patients with higher CLDN18.2 expression. These findings reinforce the potential of osemitamab as a meaningful treatment option, demonstrating consistent benefits across different PD-L1 subgroups and a favorable safety profile.
The most recent analyst rating on (HK:6628) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.
More about Transcenta Holding Limited
Transcenta Holding Limited is a biotechnology company focused on developing innovative therapeutics. The company specializes in creating monoclonal antibodies and has a market focus on treating cancers, particularly gastric and gastroesophageal junction cancers.
Average Trading Volume: 2,502,803
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.15B
Find detailed analytics on 6628 stock on TipRanks’ Stock Analysis page.